Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: A clinical update

Future Microbiology

Volumn 9, Issue 4, 2014, Pages 457-463

  Vincent, Jean Louis ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

antimicrobial resistance; flagella; ICU; lipopolysaccharide; outer membrane proteins; pneumonia; Pseudomonas; sepsis; vaccination

Indexed keywords

ANTIBIOTIC AGENT; PSEUDOMONAS VACCINE;

CLINICAL EVALUATION; CRITICALLY ILL PATIENT; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; INTENSIVIST; OUTCOME ASSESSMENT; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW; CLINICAL TRIAL (TOPIC); CRITICAL ILLNESS; CROSS INFECTION; IMMUNOLOGY; PROCEDURES; PSEUDOMONAS INFECTIONS;

CLINICAL TRIALS AS TOPIC; CRITICAL ILLNESS; CROSS INFECTION; HUMANS; IMMUNIZATION, PASSIVE; INTENSIVE CARE UNITS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS VACCINES;

EID: 84900323437     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.14.10     Document Type: Review

References (53)

1. Gessard MC. Sur les colorations bleue et verte des linges a pansements. C. R. Acad. Sci. Hebd. Seances Acad. Sci. 94, 536-538 (1882).
2. Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit. Care Med. 33, 2184-2193 (2005).
3. Vincent JL, Sakr Y, Sprung CL et al. Sepsis in European intensive care units: results of the SOAP study. Crit. Care Med. 34, 344-353 (2006).
4. Vincent JL, Rello J, Marshall J et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302, 2323-2329 (2009).
5. Poole K. Pseudomonas aeruginosa: resistance to the max. Front Microbiol. 2, 65 (2011).
6. Lang AB, Rudeberg A, Schoni MH et al. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr. Infect. Dis. J. 23, 504-510 (2004).
7. Langford DT, Hiller J. Prospective, controlled study of a polyvalent Pseudomonas vaccine in cystic fibrosis - three year results. Arch. Dis. Child. 59, 1131-1134 (1984).
8. Doring G, Meisner C, Stern M. A double-blind randomized placebo-controlled Phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc. Natl Acad. Sci. USA 104, 11020-11025 (2007).
9. Jones RJ, Roe EA, Gupta JL. Controlled trials of a polyvalent Pseudomonas vaccine in burns. Lancet 2, 977-982 (1979).
10. Kim DK, Kim JJ, Kim JH et al. Comparison of two immunization schedules for a Pseudomonas aeruginosa outer membrane proteins vaccine in burn patients. Vaccine 19, 1274-1283 (2000).
11. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348, 1546-1554 (2003).
12. Vincent JL, Marshall JC, Ñamendys-Silva SA et al. The Intensive Care Over Nations (ICON) Audit: a worldwide insight into the burden of critical illness. Lancet Respir. Med. (2014) (In Press).
13. Tumbarello M, De Pascale G, Trecarichi EM et al. Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med. 39, 682-692 (2013).
14. Croughs PD, Li B, Hoogkamp-Korstanje JA, Stobberingh E. Thirteen years of antibiotic susceptibility surveillance of Pseudomonas aeruginosa from intensive care units and urology services in The Netherlands. Eur. J.Clin. Microbiol. Infect Dis. 32, 283-288 (2013).
15. Zhang S, McCormack FX, Levesque RC, O'Toole GA, Lau GW. The flagellum of Pseudomonas aeruginosa is required for resistance to clearance by surfactant protein A. PLoS ONE 2, e564 (2007).
16. Stover CK, Pham XQ, Erwin AL et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406, 959-964 (2000).
17. Fito-Boncompte L, Chapalain A, Bouffartigues E et al. Full virulence of Pseudomonas aeruginosa requires OprF. Infect. Immun. 79, 1176-1186 (2011).
18. Tamber S, Ochs MM, Hancock RE. Role of the novel OprD family of porins in nutrient uptake in Pseudomonas aeruginosa. J. Bacteriol. 188, 45-54 (2006).
19. Wessel AK, Liew J, Kwon T, Marcotte EM, Whiteley M. Role of Pseudomonas aeruginosa peptidoglycan-associated outer membrane proteins in vesicle formation. J. Bacteriol. 195, 213-219 (2013).
20. Arhin A, Boucher C. The outer membrane protein OprQ and adherence of Pseudomonas aeruginosa to human fibronectin. Microbiology 156, 1415-1423 (2010).
21. Zhang Z, Louboutin JP, Weiner DJ, Goldberg JB, Wilson JM. Human airway epithelial cells sense Pseudomonas aeruginosa infection via recognition of flagellin by Toll-like receptor 5. Infect. Immun. 73, 7151-7160 (2005).
22. Wolfgang MC, Jyot J, Goodman AL, Ramphal R, Lory S. Pseudomonas aeruginosa regulates flagellin expression as part of a global response to airway fluid from cystic fibrosis patients. Proc. Natl Acad. Sci. USA 101, 6664-6668 (2004).
23. Mena A, Smith EE, Burns JL et al. Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J. Bacteriol. 190, 7910-7917 (2008).
24. Conrad JC, Gibiansky ML, Jin F et al. Flagella and pili-mediated near-surface single-cell motility mechanisms in P. aeruginosa. Biophys. J. 100, 1608-1616 (2011).
25. Filloux A. Protein secretion systems in Pseudomonas aeruginosa: an essay on diversity, evolution, and function. Front. Microbiol. 2, 155 (2011).
26. Shaver CM, Hauser AR. Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung. Infect. Immun. 72, 6969-6977 (2004).
27. Howell HA, Logan LK, Hauser AR. Type III secretion of ExoU is critical during early Pseudomonas aeruginosa pneumonia. MBio 4, e00032-13 (2013).
28. Hritonenko V, Mun JJ, Tam C et al. Adenylate cyclase activity of Pseudomonas aeruginosa ExoY can mediate bleb-niche formation in epithelial cells and contributes to virulence. Microb. Pathog. 51, 305-312 (2011).
29. Veesenmeyer JL, Hauser AR, Lisboa T, Rello J. Pseudomonas aeruginosa virulence and therapy: evolving translational strategies. Crit. Care Med. 37, 1777-1786 (2009).
30. De Kievit TR, Gillis R, Marx S, Brown C, Iglewski BH. Quorum-sensing genes in Pseudomonas aeruginosa biofilms: their role and expression patterns. Appl. Environ. Microbiol. 67, 1865-1873 (2001).
31. Flickinger ST, Copeland MF, Downes EM et al. Quorum sensing between Pseudomonas aeruginosa biofilms accelerates cell growth. J. Am. Chem. Soc. 133, 5966-5975 (2011).
32. Jimenez PN, Koch G, Thompson JA et al. The multiple signaling systems regulating virulence in Pseudomonas aeruginosa. Microbiol. Mol. Biol. Rev. 76, 46-65 (2012).
33. Bjarnsholt T, Jensen PO, Burmolle M et al. Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. Microbiology 151, 373-383 (2005).
34. Strateva T, Yordanov D. Pseudomonas aeruginosa - a phenomenon of bacterial resistance. J. Med. Microbiol. 58, 1133-1148 (2009).
35. Doring G, Pier GB. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 26, 1011-1024 (2008).
36. Sharma A, Krause A, Worgall S. Recent developments for Pseudomonas vaccines. Hum. Vaccin. 7, 999-1011 (2011).
37. Press releases: Crucell announces suspension of Aerugen clinical development, http://investors.crucell.com/C/132631/ PR/200607/1064252-5-6.html
38. Donta ST, Peduzzi P, Cross AS et al. Immunoprophylaxis against Klebsiella and pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group. J. Infect. Dis. 174, 537-543 (1996).
39. Westritschnig K, Hochreiter R, Wallner G, Firbas C, Schwameis M, Jilma B. A randomized, placebo-controlled Phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers. Hum. Vaccin. Immunother. 10(1), 2846-2859 (2013).
40. Intercell reports positive results from its Phase II Pseudomonas aeruginosa investigational vaccine study for certain hospital-acquired infections www.drugs.com/clinical-trials/intercell-reports-positive-results- phase-ii-10440.html
41. Confirmatory Phase II/III study assessing efficacy, immunogenicity and safety of IC43
42. Valneva provides update on Phase II/III interim analysis of its Pseudomonas aeruginosa vaccine candidate
43. Francois B, Luyt CE, Dugard A et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial. Crit. Care Med. 40, 2320-2326 (2012).
44. Minei JP, Hawkins K, Moody B et al. Alternative case definitions of ventilator-associated pneumonia identify different patients in a surgical intensive care unit. Shock 14, 331-336 (2000).
45. Novosel TJ, Hodge LA, Weireter LJ et al. Ventilator-associated pneumonia: depends on your definition. Am. Surg. 78, 851-854 (2012).
46. Horn MP, Zuercher AW, Imboden MA et al. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. Antimicrob. Agents Chemother. 54, 2338-2344 (2010).
47. Lazar H, Horn MP, Zuercher AW et al. Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA 101 in healthy volunteers. Antimicrob. Agents Chemother. 53, 3442-3446 (2009).
48. Lu Q, Rouby JJ, Laterre PF et al. Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. J. Antimicrob. Chemother. 66, 1110-1116 (2011).
49. Secher T, Fas S, Fauconnier L et al. The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem. PLoS ONE 8, e73396 (2013).
50. Worgall S. 40 years on: have we finally got a vaccine for Pseudomonas aeruginosa? Future Microbiol. 7, 1333-1335 (2012).
51. Wu W, Huang J, Duan B et al. Th17- stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia. Am. J. Respir. Crit. Care Med. 186, 420-427 (2012).
52. Campodonico VL, Llosa NJ, Bentancor LV, Maira-Litran T, Pier GB. Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice. Infect. Immun. 79, 3455-3464 (2011).
53. Kamei A, Coutinho-Sledge YS, Goldberg JB, Priebe GP, Pier GB. Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection. Infect. Immun. 79, 1289-1299 (2011).